Section of Neuropsychiatry 2021 Virtual Conference

New neuropsychiatric paradigms in a post-pandemic world

About the conference

The RANZCP Section of Neuropsychiatry 2021 Virtual Conference will take place online from 12-13 November 2021 and explore the theme ‘New neuropsychiatric paradigms in a post-pandemic world’.

Spread over two half-days, the program is packed with plenary sessions and symposia that capture the zeitgeist of contemporary neuropsychiatric practice. In a year ravaged by the COVID 19 pandemic, we invite you to join us in celebrating innovations and clinical discoveries that typify neuroscience and neuropsychiatry and are a testament to the resilience of scientific enquiry the world over.

We hope you will join us for what promises to be an exciting and stimulating conference and look forward to seeing you there.

Dr Adith Mohan and Professor Perminder Sachdev
Conference Co-convenors

12–13 November 2021

Add to Calendar

Register now



Professor Richard Kanaan

Richard Kanaan studied mathematics and philosophy in Oxford and Los Angeles before training in medicine and psychiatry in London.  Professor Kanaan was a clinician and academic at the Maudsley Hospital/Institute of Psychiatry in London until he was appointed chair of psychiatry at Austin Hospital, and professor of psychiatry at the University of Melbourne in 2013. His special interests include conversion disorder (functional neurological disorder), schizophrenia and the philosophy of psychiatry.

Dr Paul Liknaitzky

Paul Liknaitzky is head of the Clinical Psychedelic Research Lab within the Turner Institute and the Dept of Psychiatry at Monash University, and chief principal investigator on a program of psychedelic trials at Monash University.

Over the past few years, Dr Liknaitzky has played a central role in establishing the field of psychedelic medicine in Australia. He is an investigator on a number of Australia’s first few ethically approved psychedelic trials, leads Australia’s first clinical psychedelic lab, supervises Australia’s first experimental psychedelic PhD student, coordinates Australia’s first applied psychedelic therapist training programs, has obtained the first industry funding and partnership for psychedelics in Australia, and is establishing Australia’s largest psychedelic trial.

Professor Colleen Loo

Colleen Loo is a psychiatrist, NHMRC Leadership Fellow and professor of psychiatry at UNSW and the Black Dog Institute, Sydney, Australia. She is an internationally recognised clinical expert and researcher in the field of electroconvulsive therapy, transcranial magnetic stimulation, transcranial direct current stimulation and ketamine, and led the first Australian RCTs of these interventions in depression.  She has published over 200 peer-reviewed papers and has received grant funding from the Australian NHMRC, US-based NARSAD and Stanley Foundations, UK NHS/MRC and Singapore NMC.

Professor Loo contributes to ECT, neurostimulation and novel treatments research and practice and policy; providing advice to Australian government health departments, the Royal Australian and New Zealand College of Psychiatrists, and several international guidelines. She was president of the International Society for ECT and Neurostimulation (ISEN) 2018-2020. andhas served on the editorial boards of the two leading international brain stimulation journals: Journal of ECT, andBrain Stimulation.

Professor Iain McGregor

Iain McGregor is professor of psychopharmacology and academic director of the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney, Australia. Dr McGregor’s research is focused on the discovery and development of new medications for the treatment of epilepsy, pain, cancer, addictions, and mental health conditions. He has a strong interest in medicinal cannabis, with more than 25 years of experience in cannabinoid research. The Lambert Initiative for Cannabinoid Therapeutics was formed in 2015 with a generous gift from the Lambert family to the University of Sydney. It aims to fast-track research into the therapeutic benefits of cannabinoids for various disease states.


View the conference program [PDF; 172 KB]


Registration category  Virtual registration 
RANZCP Fellow / Affiliate / other medical practitioner    $200
RANZCP Trainee / Retired Fellow / Allied Health   $150
University student (medicine/psychology)   $75


Register now

Registration includes:

  • Access to the virtual platform and all sessions during the conference 
  • Access to view all presentation abstracts and speaker information
  • Access to view all presentations and conference content on demand for three months post conference


Please note that registrations for this conference must be paid for via credit or debit card through our online booking system. Payment via invoice is not available. A receipt will be provided upon completion of your booking.

Terms and conditions 

Cancellation policy 

All requests for cancellation or substitution must be made in writing and sent to Cancellations received before 12 October 2021 will incur a $25 administration fee. No refunds will be issued after this date. Substitute delegates may be accepted. Please contact for any enquiries.